Abstract
Hepatitis C virus (HCV) has deceived researchers for seventeen years now and although the current therapy regimen has been optimized by the development of pegylated interferon-α and the addition of ribavirin, no new agent to treat HCV infected patients has yet reached the market. A new era is approaching the HCV research due to new developments for the propagation of the virus in a cell-based system, which may lead to new drug innovations. Efforts in the search of new treatments for HCV infected patients are either focused on direct antiviral drugs, targeting the structural components or enzymes encoded by the virus, or indirect antiviral drugs, targeting host cell components (immunomodulators etc.). An inspection of the drug pipeline for HCV reveals representatives from both classes and of different mechanisms of action. Among the direct acting antiviral agents, inhibitors of the NS3 protease, the NS5B polymerase, and the viral RNA are the most intensively explored. However, there is also on-going and promising preclinical research, in different stages, on other potential targets as the structural protein E2 (for cell-entry inhibitors), the NS3 helicase, the p7 ion-channel, and the multifunctional NS5A protein. The combat of HCV will certainly require a combination of drugs of different mechanisms in order to reduce the emergence of resistance. The latest developments in the discovery of agents to treat HCV are reviewed, with special focus on direct small-molecule antiviral drugs, from a medicinal chemistry perspective.
Keywords: HCV, Hepatitis C, inhibitors, antiviral drugs, antiviral targets, NS3 protease, NS3 helicase, NS5B polymerase
Current Topics in Medicinal Chemistry
Title: New Developments in the Discovery of Agents to Treat Hepatitis C
Volume: 8 Issue: 7
Author(s): Robert Ronn and Anja Sandstrom
Affiliation:
Keywords: HCV, Hepatitis C, inhibitors, antiviral drugs, antiviral targets, NS3 protease, NS3 helicase, NS5B polymerase
Abstract: Hepatitis C virus (HCV) has deceived researchers for seventeen years now and although the current therapy regimen has been optimized by the development of pegylated interferon-α and the addition of ribavirin, no new agent to treat HCV infected patients has yet reached the market. A new era is approaching the HCV research due to new developments for the propagation of the virus in a cell-based system, which may lead to new drug innovations. Efforts in the search of new treatments for HCV infected patients are either focused on direct antiviral drugs, targeting the structural components or enzymes encoded by the virus, or indirect antiviral drugs, targeting host cell components (immunomodulators etc.). An inspection of the drug pipeline for HCV reveals representatives from both classes and of different mechanisms of action. Among the direct acting antiviral agents, inhibitors of the NS3 protease, the NS5B polymerase, and the viral RNA are the most intensively explored. However, there is also on-going and promising preclinical research, in different stages, on other potential targets as the structural protein E2 (for cell-entry inhibitors), the NS3 helicase, the p7 ion-channel, and the multifunctional NS5A protein. The combat of HCV will certainly require a combination of drugs of different mechanisms in order to reduce the emergence of resistance. The latest developments in the discovery of agents to treat HCV are reviewed, with special focus on direct small-molecule antiviral drugs, from a medicinal chemistry perspective.
Export Options
About this article
Cite this article as:
Ronn Robert and Sandstrom Anja, New Developments in the Discovery of Agents to Treat Hepatitis C, Current Topics in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/156802608783955647
DOI https://dx.doi.org/10.2174/156802608783955647 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Smad3-Mediated Signals Showing Similarities and Differences Between Epithelial and Mesenchymal Cells in Human Chronic Liver Diseases
Current Enzyme Inhibition The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Uncontrolled Hypertension and Oncology: Clinical Tips
Current Vascular Pharmacology Defining Novel Targets for Intervention in Rheumatoid Arthritis: An Overview
Current Rheumatology Reviews Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
Current Medicinal Chemistry Development of Radioligands for In Vivo Imaging of Type 1 Cannabinoid Receptors (CB1) in Human Brain
Current Pharmaceutical Design The Interaction of Dietary Fibres with the Colon
Current Nutrition & Food Science Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Biologic Therapies Against Inflammatory Bowel Disease: A Dysregulated Immune System and the Cross Talk with Gastrointestinal Mucosa Hold the Key
Current Molecular Pharmacology Drug Targets in Stress-Related Disorders
Current Medicinal Chemistry Recent Advances in Coumarins and 1-Azacoumarins as Versatile Biodynamic Agents
Current Medicinal Chemistry Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Advances in the Pharmacologic Treatment of Hepatocellular Carcinoma
Current Clinical Pharmacology Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Current Pharmaceutical Design Targeting Stenosis with Nucleotide-Hydrolyzing Enzymes
Current Pharmaceutical Biotechnology Hemopoietic Progenitor Cells and Hemopoietic Factors: Potential Targets for Treatment of Allergic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology Toll-Like Receptors: Sensor Molecules for Detecting Damage to the Nervous System
Current Protein & Peptide Science